Neil Conlon
@neilconlon.bsky.social
Assistant Professor in Biotherapeutics
Cancer biologist @ DCU
Science/sports/all-round nerd
(he/him)
Cancer biologist @ DCU
Science/sports/all-round nerd
(he/him)
Reposted by Neil Conlon
BREAKING: The #FDA has approved datopotamab deruxtecan (Dato-DXd) for the treatment of patients with unresectable or metastatic HR+/HER2- breast cancer who have received prior systemic therapy. #bcsm
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
FDA Approves Dato-DXd in HR+/HER2– Breast Cancer
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.
www.targetedonc.com
January 17, 2025 at 7:28 PM
BREAKING: The #FDA has approved datopotamab deruxtecan (Dato-DXd) for the treatment of patients with unresectable or metastatic HR+/HER2- breast cancer who have received prior systemic therapy. #bcsm
www.targetedonc.com/view/fda-app...
www.targetedonc.com/view/fda-app...
Trading pipettes for paintbrushes and lab coats for aprons—our Christmas lab outing was all about pottery, painting, and pizza
December 14, 2024 at 8:45 PM
Trading pipettes for paintbrushes and lab coats for aprons—our Christmas lab outing was all about pottery, painting, and pizza
Reposted by Neil Conlon
Congrats to Myra Castel on passing her viva and obtaining her PhD! It was a pleasure to supervise the project funded through our @researchireland.bsky.social ACORN project. Thanks to the co-supervisory panel members @neilconlon.bsky.social, Dr Naomi Walsh, Prof John Crown @dcu-lsi.bsky.social
December 11, 2024 at 1:48 PM
Congrats to Myra Castel on passing her viva and obtaining her PhD! It was a pleasure to supervise the project funded through our @researchireland.bsky.social ACORN project. Thanks to the co-supervisory panel members @neilconlon.bsky.social, Dr Naomi Walsh, Prof John Crown @dcu-lsi.bsky.social
